High Sensitivity Troponin T and Nt-Probnp in Patients Receiving Chimeric Antigen Receptor (Car) T-Cell Therapy

Hu, Jiun-Ruey; Patel, Ameet; Su, Yan-Ru; Dahlman, Kimberly B.; Tomasek, Kelsey; Huang, Shi; Zhang, Yueli; O’Neil, Richard T.; O’Neal, Jamye F.; Johnson, Douglas B.; Salem, Joe‐Elie; Oluwole, Olalekan O.; Moslehi, Javid

doi:10.1016/s0735-1097(21)04645-3

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoint inhibitors can cause inflammatory toxicities, including myocarditis 176 ; however, adverse effects can also include metabolic toxicities, including diabetes 177 . Cellular therapies can result in cytokine release syndrome, which can manifest with mild to life-threatening symptoms, including severe hypotension and vascular leak 175,[178][179][180] . Although the mechanisms of these cardiovascular toxicities are not clear, metabolic perturbations resulting from cytokine release syndrome could contribute to systemic toxicities.…”

Section: Metabolic Effects Of Anticancer Therapiesmentioning

confidence: 99%

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer

2022

View full text Add to dashboard Cite

Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation of cancer growth by cardiac dysfunction. As a result, interest has increased in understanding the fundamental biological mechanisms that are central to the relationship between cardiovascular disease and cancer. Metabolism, appropriate regulation of energy, energy substrate utilization, and macromolecular synthesis and breakdown are fundamental processes for cellular and organismal survival. In this Review, we explore the emerging data identifying metabolic dysregulation as an important theme in cardio-oncology. We discuss the growing recognition of metabolic reprogramming in cardiovascular disease and cancer and view the novel area of cardio-oncology through the lens of metabolism.

show abstract